Only line in the announcement potentially relating to potency assays is the last bit in my opinion - "...seeking to address all remaining product characterization issues".
Potency assay stuff is product characterization stuff - so that could be an acknowledgement (in an obscure general way - that they don't have an all clear on potency assay approach) but as I said "product characterization" is a broader term. It could pick up screening product for viral contamination etc and a bunch of other stuff unrelated to potency assays (as specific metrics intended to track product potency).
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA, page-306
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
0.020(1.81%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.12 | $1.14 | $1.12 | $4.898M | 4.355M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 596693 | $1.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 50805 | 4 |
View Market Depth
| Last trade - 16.10pm 04/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.13 |
Change
0.020 ( 0.92 %) |
||||
| Open | High | Low | Volume | ||
| $1.12 | $1.14 | $1.12 | 1420559 | ||
| Last updated 15.59pm 04/06/2024 ? | |||||
| MSB (ASX) Chart |